China National Accord Medicines Corporation Ltd.
The Third Quarterly Report for 2013
October 2013
1
Section I. Important Notice
Board of Directors, Supervisory Committee, all directors, supervisors and senior executives of China National
Accord Medicines Corporation Ltd. (hereinafter referred to as the Company) hereby confirm that there are no any
fictitious statements, misleading statements, or important omissions carried in this report, and shall take all
responsibilities, individual and/or joint, for the reality, accuracy and completion of the whole contents.
All directors are present the meeting of the Board for deliberating the Third Quarter Report of the Company in
person.
Yan Zhigang, person in charge of the Company, head of the accounting works Wei Pingxiao and Chi Guoguang,
accounting body principals (accountant in charge) hereby confirm that the Financial Report of the Third Quarterly
Report is authentic, accurate and complete.
2
Section II. Main accounting data and changes of shareholders
I. Main accounting data and index
Whether it has retroactive adjustment or re-statement on previous accounting data for accounting policy changed and accounting
error correction or not
□Yes √ No
Current period-end Period-end of last year Increase/decrease (%)
Total assets(RMB) 10,586,761,136.29 9,295,839,939.64 13.89%
Net assets attributable to
shareholders of listed company 2,120,961,252.67 1,775,943,028.96 19.43%
(RMB)
Increase/decrease in
Increase/decrease in comparison with
Year-begin to end of
Current period comparison with same year-begin to
the Period
period of last year (%) Period-end of last year
(%)
Operating revenue (RMB) 5,544,642,435.73 18.14% 15,676,355,126.17 16.15%
Net profit attributable to
shareholders of the listed company 135,890,437.07 16.1% 396,685,115.71 11.09%
(RMB)
Net profit attributable to
shareholders of the listed company
129,582,036.76 17.38% 389,762,224.19 8.66%
after deducting non-recurring gains
and losses(RMB)
Net cash flow arising from
-- -- 244,812,738.44 1,925.71%
operating activities(RMB)
Basic earnings per share
0.472 16.26% 1.377 11.14%
(RMB/Share)
Diluted earnings per share
0.472 16.26% 1.377 11.14%
(RMB/Share)
Weighted average ROE (%) 6.62% -0.66% 20.39% -3.34%
Items and amount of extraordinary profit (gains)/losses
√Applicable □Not applicable
In RMB
Amount from year-begin to
Item Note
end of the Period
3
Gains/losses from the disposal of non-current asset (including the Earnings from disposal of fixed
694,174.60
write-off that accrued for impairment of assets) assets
Mainly refers to the enterprise
Governmental subsidy reckoned into current gains/losses (not support fund from Nanning
including the subsidy enjoyed in quota or ration according to Economic & Technological
17,068,198.93
national standards, which are closely relevant to enterprise’s Development Zone RMB 7.05
business) million and vary finance discount
and government subsidies etc.
Reversal of impairment reserve for account receivable with
1,675,804.53
separate impairment testing
Mainly including the disposal of
amount unable to paid RMB
10.49 million; in line with the
Other non-operating income and expenditure except for the
-10,760,186.44 prudence principle, accrued
aforementioned items
liabilities RMB 22.04 million of
unsettled lawsuits for the Chebei
Project was accrued etc.
Less: impact on income tax 1,638,912.53
Impact on minority shareholders’ equity (post-tax) 116,187.57
Total 6,922,891.52 --
Concerning the extraordinary profit (gain)/loss defined by Q&A Announcement No.1 on Information Disclosure for Companies
Offering Their Securities to the Public --- Extraordinary Profit/loss, and the items defined as recurring profit (gain)/loss according to
the lists of extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their
Securities to the Public --- Extraordinary Profit/loss, explain reasons
□ Applicable √ Not applicable
II. Statement of the total shareholders and shares-held of top ten shareholders at end of the
Period
In Share
Total shareholders at period-end 11,293
Shares-held of top ten shareholders
Amount of Number of share pledged/frozen
Nature of Proportion of Amount of shares
Shareholders restricted shares
shareholder shares held (%) held State of share Amount
held
Sinopharm Group State-owned
38.33% 110,459,748 0
Co., Ltd. corporate
National Council Domestic non
for Social state-owned 2.78% 8,000,139 0
Security Fund ? corporate
4
116
VALUE
Overseas
PARTNERS 2.67% 7,697,761 0
corporate
CLASSIC FUND
HTHK/CMG
FSGUFP-CMG
Overseas
FIRST STATE 2.44% 7,032,720 0
corporate
CHINA
GROWTH FD
ICBC－
HARVEST Domestic non
THEME NEW state-owned 2.43% 7,001,664 0
POWER STOCK corporate
FUND
National Council
Domestic non
for Social
state-owned 2.31% 6,649,548 0
Security Fund ?
corporate
106
CCB ? China
Domestic non
AMC Advantage
state-owned 2.23% 6,416,489 0
Growth Stock
corporate
Investment Fund
Bank of China ?
Domestic non
Harvest Research
state-owned 1.75% 5,043,249 0
Selected Stock
corporate
Fund
ICBC?Harvest Domestic non
Strategy Growth state-owned 1.49% 4,296,255 0
Mix Stock Fund corporate
ICBC?UBS Domestic non
Core Enterprise state-owned 1.44% 4,160,911 0
Stock Fund corporate
Particular about top ten shareholders with un-restrict shares held
Type of shares
Shareholders Amount of un-restrict shares held
Type Amount
RMB ordinary
Sinopharm Group Co., Ltd. 110,459,748 110,459,748
shares
National Council for Social Security RMB ordinary
8,000,139 8,000,139
Fund ? 116 shares
VALUE PARTNERS CLASSIC 7,697,761 Domestically 7,697,761
5
FUND listed foreign
shares
Domestically
HTHK/CMG FSGUFP-CMG FIRST
7,032,720 listed foreign 7,032,720
STATE CHINA GROWTH FD
shares
ICBC－HARVEST THEME NEW RMB ordinary
7,001,664 7,001,664
POWER STOCK FUND shares
National Council for Social Security RMB ordinary
6,649,548 6,649,548
Fund ? 106 shares
CCB ? China AMC Advantage RMB ordinary
6,416,489 6,416,489
Growth Stock Investment Fund shares
Bank of China ? Harvest Research RMB ordinary
5,043,249 5,043,249
Selected Stock Fund shares
ICBC?Harvest Strategy Growth RMB ordinary
4,296,255 4,296,255
Mix Stock Fund shares
ICBC?UBS Core Enterprise Stock RMB ordinary
4,160,911 4,160,911
Fund shares
ICBC－HARVEST THEME NEW POWER STOCK FUND and ICBC?Harvest Strategy
Growth Mix Stock Fund has the same fund manager of Harvest Fund Management Co., Ltd.;
as an investment manager, VALUE PARTNERS is in charge of 19 funds and entrusted
Explanation on associated
accounts in total. VALUE PARTNERS CLASSIC FUND, one of the top ten shareholders, is
relationship among the aforesaid
one of the VALUE PARTNERS; it is unknown that there exists no associated relationship or
shareholders
belongs to the consistent actionist among the other tradable shareholders regulated by the
Management Measure of Information Disclosure on Change of Shareholding for Listed
Companies.
Whether has an agreed-to-buyback dealing in reporting period
□Yes √No
6
Section III. Important events
I. Particular about major changes from items of main accounting statements and financial
indexes as well as reasons
1. Other account receivable: increase RMB 11.69 million over that of period-begin with growth rate of 35.43%, which mainly
because the housing rentals as well as deposit and margin increased;
2. Other current assets: decrease RMB5.44 million over that of period-begin with growth rate of -67.26%, mainly because the
retained VAT decreased;
3. Construction in progress: increase RMB 67.33 million over that of period-begin with growth rate of 64.77%, mainly because as for
the Guanlan Base Phase II project and technical innovation of workshop of subsidiary of the Company, investment for the above said
projects increased;
4. Short-term loans: increase RMB 667.54 million over that of period-begin with growth rate of 39.55%, mainly because the loan in
credit and discounted notes receivable increased;
5. Account received in advance: increase RMB 11.21 million over that of period-begin with growth rate of 32.03%, mainly because
the account paid in advance for goods from the clients increased in the Period;
6. Taxes payable: increase RMB 39.99 million over that of period-begin with growth rate of 77.81%, mainly because profit growth
arising from the growth of sales and purchasing, the vary taxes increased correspondingly;
7. Non-current liability due within one year: decrease RMB 31.10 million over that of period-begin in balance with growth rate of
-43.73%, mainly because the loans due within one year were pay-back by the subsidiary of the Company;
8. Other current liability: decrease RMB 399.01 million over that of period-begin in balance with growth rate of -100.00%, mainly
because the short-term financing bonds, issued last year, are due for repayment;
9. Long-term loans: decrease RMB 82.21 million over that of period-begin in balance with growth rate of -100.00%, mainly because
long-term loans due within one year was re-classified to non-current liability due within one year;
10. Long-term payables: decrease RMB 30,000 over that of period-begin in balance with growth rate of -100.00%, mainly because
seniority compensation for the staff of subsidiary of the Company was paid completed in the Period;
11. Accrued liability: increase RMB 22.04 million over that of period-begin in balance with growth rate of 100.00%, mainly because
in line with the prudence principle, the compensation for lawsuits are accrued;
12. Minority interest: a y-o-y growth of RMB 3.16 million with growth rate of 42.55%, mainly because subsidiary of minority’s
gains a y-o-y growth of profit in the Period and minority equity of subsidary was acquired in the Period;
13. Tax refunds: a y-o-y growth of RMB 6.60 million with growth rate of 400.91%, mainly because the tax refunds received by
subsidairy of the Company increased, which is benefit from the government’s supporting policy;
14. Other cash received with operation activities concerned: a y-o-y down of RMB 28.93 million with growth rate of -35.01%,
mainly because at same period of last year, the subsidiary, which was purchased newly, received the business loans paid by original
shareholders, and no such business occurred in the Period;
15. Net cash flow arising from operating activities: a y-o-y growth of RMB 232.73 million with growth rate of 1925.71%, mainly
because the Company has a y-o-y growth in sales and more payments are calling back;
16. Cash received from investment earnings: a y-o-y growth of RMB 14.63 million with growth rate of 108.22%, mainly because
Main Luck Pharmaceutical, the affiliated company, has a y-o-y growth in cash dividends;
17. Net cash received from disposal of fixed assets, intangible assets and other long-term assets: a y-o-y down of RMB 51.05 million
7
with growth rate of -94.40%, mainly because at same period of last year, subsidiary of the Company received a compensation for
government’s renewal of old district, and no such business occurred in the Period;
18. Cash paid for purchasing fixed assets, intangible assets and other long-term assets: a y-o-y down of RMB 73.11 million with
growth rate of -49.92%, mainly because at same period of last year, part of the funds of tail for construction was paid, and no such
amount being paid in the Period;
19. Net cash paid from subsidiary and other operation units: a y-o-y down of RMB 55.30 million with growth rate of -99.73%,
mainly because at same period of last year, amount of equity acquisition was paid for subsidiary purchased, and no such amount
being paid in the Period;
20. Net cash flow arising from investment activities: a y-o-y growth of RMB 91.99 million with growth rate of 68.49%, mainly
because at same period of last year, part of the funds of tail for construction and amount of equity acquisition for subsidiary
purchased were paid, and no such amount being paid in the Period;
21. Cash received from bond issuance: a y-o-y down of RMB 398.40 million with growth rate of -100.00%, mainly because at same
period of last year, short-term financing bonds issued, and no such business occurred in the Period;
22. Other cash received with financing activities concerned: a y-o-y growth of RMB 147.37 million with growth rate of 58.33%,
mainly because entrust loans increased in the Period;
23. Net cash flow arising from financing activities: a y-o-y down of RMB 115.96 million with growth rate of -77.13%, mainly
because the financing scale down y-o-y;
24. Influence on cash and cash equivalents due to fluctuation in exchange rate: a y-o-y down of RMB 10,000 with growth rate of
-181.73%, mainly because more foreign currency were held and fluctuation of foreign exchange rate.
II. Progress and influence of the main events as well as solution analysis specification
The 19th meeting of 6th session of the Board and third extraordinary shareholders’ general meeting were held on 19 July 2013 and
13 September 2013 respectively for deliberated and approved the relevant proposal of private placement of A share successively.
The issuance still in process recently.
Query indexes of disclosure website for
Overview Disclosure date
interim report
Relevant proposal of “The Company
Accords with the Private Placement of A
2013-07-22 http://www.cninfo.com.cn
share” was deliberated and approved in
19th meeting of 6th session of the Board
Relevant proposal of “The Company
Accords with the Private Placement of A
share” was deliberated and approved in 2013-09-13 http://www.cninfo.com.cn
third extraordinary shareholders’ general
meeting
III. Estimation of operation performance for year of 2013
Estimation on accumulative net profit from the beginning of the year to the end of next report period to be loss probably or the
warning of its material change compared with the corresponding period of the last year and explanation on reason
□ Applicable √ Not applicable
8
IV. In the report period, reception of research, communication and interview
Contents discussed and
Time Place Way Type Reception
material provided
Visit the company, and
CITIC Securities,
Building of know the impacts of the
CMB Securities
Shenzhen Accord industry development
2013-09-06 Field research Institution and China
Pharmaceutical change by Medical
Merchant Fund
Co., Ltd Reform Policies, no files
Management
provided.
Visit the company, and
Building of know the impacts of the
Orient Securities
Shenzhen Accord industry development
2013-09-12 Field research Institution and Zelong
Pharmaceutical change by Medical
Investment
Co., Ltd Reform Policies, no files
provided.
9
Section IV. Financial Statement
I. Financial statement
1. Consolidated Balance Sheet
Prepared by China National Accord Medicines Corporation Ltd.
In RMB
Item Closing balance Opening balance
Current assets:
Monetary funds 874,835,748.68 953,992,070.61
Settlement provisions
Capital lent
Transaction finance asset
Notes receivable 713,392,429.09 650,860,240.37
Accounts receivable 5,528,903,954.77 4,393,325,300.66
Accounts paid in advance 69,023,952.80 89,512,381.34
Insurance receivable
Reinsurance receivables
Contract reserve of reinsurance
receivable
Interest receivable
Dividend receivable
Other receivables 44,671,482.93 32,985,425.60
Purchase restituted finance asset
Inventories 1,880,726,394.46 1,734,679,063.78
Non-current asset due within one
year
Other current assets 2,645,426.73 8,080,607.66
Total current assets 9,114,199,389.46 7,863,435,090.02
Non-current assets:
Granted loans and advances
Finance asset available for sales
Held-to-maturity investment
Long-term account receivable
Long-term equity investment 123,383,164.59 121,019,845.50
10
Investment real estate 80,063,020.48 88,315,429.63
Fixed assets 658,774,130.26 690,487,633.12
Construction in progress 171,288,456.76 103,955,350.80
Engineering material
Disposal of fixed asset
Productive biological asset
Oil and gas asset
Intangible assets 150,985,065.07 155,155,071.20
Expense on Research and
5,495,374.62 5,002,441.27
Development
Goodwill 85,228,833.15 85,228,833.15
Long-term expenses to be
18,282,508.96 19,742,990.45
apportioned
Deferred income tax asset 59,467,228.92 49,509,529.97
Other non-current asset 119,593,964.02 113,987,724.53
Total non-current asset 1,472,561,746.83 1,432,404,849.62
Total assets 10,586,761,136.29 9,295,839,939.64
Current liabilities:
Short-term loans 2,355,345,730.33 1,687,810,294.37
Loan from central bank
Absorbing deposit and interbank
deposit
Capital borrowed
Transaction financial liabilities
Notes payable 1,130,651,004.35 1,105,275,538.24
Accounts payable 3,923,469,415.46 3,197,354,275.46
Accounts received in advance 46,215,382.54 35,002,695.02
Selling financial asset of repurchase
Commission charge and
commission payable
Wage payable 150,802,987.55 155,994,408.20
Taxes payable 91,378,500.28 51,390,674.43
Interest payable 14,562,775.30 13,035,821.07
Dividend payable
Other accounts payable 379,555,163.76 413,831,307.40
Reinsurance payables
Insurance contract reserve
11
Security trading of agency
Security sales of agency
Non-current liabilities due within 1
40,022,450.00 71,127,275.00
year
Other current liabilities 0.00 399,014,838.05
Total current liabilities 8,132,003,409.57 7,129,837,127.24
Non-current liabilities:
Long-term loans 0.00 82,205,562.71
Bonds payable
Long-term account payable 0.00 32,259.60
Payables for specific projects 4,287,000.00 4,487,000.00
Projected liabilities 22,040,000.00 0.00
Deferred income tax liabilities 25,392,910.55 26,619,273.68
Other non-current liabilities 213,358,245.92 213,607,504.21
Total non-current liabilities 265,078,156.47 326,951,600.20
Total liabilities 8,397,081,566.04 7,456,788,727.44
Owner’s equity (or shareholders’
equity):
Paid-up capital (or share capital) 288,149,400.00 288,149,400.00
Capital surplus 5,750,338.57 5,550,338.57
Less: Inventory shares
Reasonable reserve
Surplus reserve 99,360,384.15 99,360,384.15
Provision of general risk
Retained profit 1,727,701,129.95 1,382,882,906.24
Balance difference of foreign
currency translation
Total owner’s equity attributable to
2,120,961,252.67 1,775,943,028.96
parent company
Minority interests 68,718,317.58 63,108,183.24
Total owner’s equity(or shareholders’
2,189,679,570.25 1,839,051,212.20
equity)
Total liabilities and owner’s equity(or
10,586,761,136.29 9,295,839,939.64
shareholders’ equity)
Legal representative: Yan Zhigang
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Chi Guoguang
2. Balance Sheet of parent company
Prepared by China National Accord Medicines Corporation Ltd.
In RMB
12
Item Closing balance Opening balance
Current assets:
Monetary funds 186,324,058.63 160,633,355.13
Transaction finance asset
Notes receivable 7,899,979.39 376,521.35
Accounts receivable 492,656,578.34 364,688,936.84
Accounts paid in advance 792,976.25 2,944,282.55
Interest receivable 1,296,486.69
Dividend receivable
Other receivables 996,841,041.42 971,859,991.32
Inventories 160,050,715.93 130,552,057.09
Non-current asset due within one
year
Other current assets 39,482.38 262,096.80
Total current assets 1,845,901,319.03 1,631,317,241.08
Non-current assets:
Finance asset available for sales
Held-to-maturity investment
Long-term account receivable
Long-term equity investment 1,571,412,658.97 1,469,049,339.88
Investment real estate 5,839,972.36 7,392,314.49
Fixed assets 23,685,533.03 27,728,901.07
Construction in progress 11,108,502.99 545,247.24
Engineering material
Disposal of fixed asset
Productive biological asset
Oil and gas asset
Intangible assets 38,188,195.16 37,903,901.08
Expense on Research and
Development
Goodwill
Long-term expenses to be
7,063,788.45 7,893,858.54
apportioned
Deferred income tax asset 2,983,190.69 2,929,885.67
Other non-current asset 8,455,398.00 8,350,000.00
Total non-current asset 1,668,737,239.65 1,561,793,447.97
13
Total assets 3,514,638,558.68 3,193,110,689.05
Current liabilities:
Short-term loans 957,000,000.00 452,004,475.38
Transaction financial liabilities
Notes payable 187,332,495.87 176,012,796.90
Accounts payable 410,994,028.54 282,426,136.11
Accounts received in advance 32,457.40 477,717.18
Wage payable 29,156,514.29 28,849,468.43
Taxes payable 4,492,931.15 715,642.50
Interest payable 2,279,562.33 7,091,864.58
Dividend payable
Other accounts payable 274,163,153.43 575,130,189.97
Non-current liabilities due within 1
year
Other current liabilities 399,014,838.05
Total current liabilities 1,865,451,143.01 1,921,723,129.10
Non-current liabilities:
Long-term loans
Bonds payable
Long-term account payable
Special accounts payable 800,000.00 1,000,000.00
Projected liabilities
Deferred income tax liabilities 3,773,319.00 3,773,319.00
Other non-current liabilities
Total non-current liabilities 4,573,319.00 4,773,319.00
Total liabilities 1,870,024,462.01 1,926,496,448.10
Owner’s equity (or shareholders’
equity):
Paid-up capital (or share capital) 288,149,400.00 288,149,400.00
Capital public reserve 14,548,726.93 14,348,726.93
Less: Inventory shares
Reasonable reserve
Surplus public reserve 99,360,384.15 99,360,384.15
General risk reserve
Retained profit 1,242,555,585.59 864,755,729.87
Balance difference of foreign
14
currency translation
Total owner’s equity(or shareholders’
1,644,614,096.67 1,266,614,240.95
equity)
Total liabilities and owner’s equity(or
3,514,638,558.68 3,193,110,689.05
shareholders’ equity)
Legal representative: Yan Zhigang
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Chi Guoguang
3. Consolidated Profit Statement (this report period)
Prepared by China National Accord Medicines Corporation Ltd.
In RMB
Item Amount in this period Amount in last period
I. Total operating revenue 5,544,642,435.73 4,693,270,824.15
Including: Operating revenue 5,544,642,435.73 4,693,270,824.15
II. Total operating cost 5,386,462,164.01 4,553,798,457.73
Including: Operating cost 5,101,666,921.65 4,287,493,976.95
Operating tax and extras 9,640,431.13 9,602,518.29
Sales expenses 110,789,296.79 110,788,641.71
Administration expenses 120,244,653.35 102,852,218.88
Financial expenses 43,166,999.25 34,776,427.52
Losses of devaluation of
953,861.84 8,284,674.38
asset
Investment income (Loss is
11,938,333.75 9,003,930.24
listed with “-”)
Including: Investment
income on affiliated company and joint 11,938,333.75 9,003,930.24
venture
III. Operating profit (Loss is listed
170,118,605.47 148,476,296.66
with “-”)
Add: Non-operating income 7,140,905.91 7,963,730.94
Less: Non-operating expense 155,387.82 586,303.05
Including: Disposal loss
128,040.97 41,703.16
of non-current asset
IV. Total Profit (Loss is listed with
177,104,123.56 155,853,724.55
“-”)
Less: Income tax expense 37,642,385.77 34,568,724.21
V. Net profit (Net loss is listed with “-”) 139,461,737.79 121,285,000.34
Net profit Attributable to equity
135,890,437.07 117,041,639.67
holders of the Company
Minority shareholders’ gains and
3,571,300.72 4,243,360.67
losses
15
VI. Earnings per share: -- --
i. Basic earnings per share 0.472 0.406
ii. Diluted earnings per share 0.472 0.406
VIII. Total comprehensive income 139,461,737.79 121,285,000.34
Total consolidated income attributable
135,890,437.07 117,041,639.67
to owners of parent company
Total consolidated income attributable
3,571,300.72 4,243,360.67
to minority shareholders
Legal representative: Yan Zhigang
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Chi Guoguang
4. Profit Statement of parent company (this report period)
Prepared by China National Accord Medicines Corporation Ltd.
In RMB
Items Amount in this period Amount in last period
I. Operating income 677,759,418.03 549,406,861.76
Less: operating cost 646,491,560.76 524,292,949.74
Operating tax and extras 1,456,413.47 1,454,213.60
Sales expenses 14,384,558.76 10,533,270.73
Administration expenses 21,547,551.30 21,699,810.10
Financial expenses 131,996.79 3,515,554.18
Losses of devaluation of asset -68,838.55 -297,612.60
Investment income (Loss is
17,107,709.21 9,003,930.24
listed with “-”)
Including: Investment income
11,938,333.75 9,003,930.24
on affiliated company and joint venture
II. Operating profit (Loss is listed
10,923,884.71 -2,787,393.75
with “-”)
Add: Non-operating income 3,470,686.99 505,506.53
Less: Non-operating expense 2,000.00 8.38
III. Total Profit (Loss is listed with
14,392,571.70 -2,281,895.60
“-”)
Less: Income tax expense 87.66
IV. Net profit (Net loss is listed with
14,392,484.04 -2,281,895.60
“-”)
V. Earnings per share -- --
VII. Total comprehensive income 14,392,484.04 -2,281,895.60
Legal representative: Yan Zhigang
Person in charge of accounting works: Wei Pingxiao
16
Person in charge of accounting institution: Chi Guoguang
5. Consolidated profit statement (from year-begin to end of this period)
Prepared by China National Accord Medicines Corporation Ltd.
In RMB
Item Amount in this period Amount in last period
I. Total operating income 15,676,355,126.17 13,496,523,170.35
Including: Operating income 15,676,355,126.17 13,496,523,170.35
Interest income
Insurance gained
Commission charge and
commission income
II. Total operating cost 15,208,026,096.92 13,055,103,583.27
Including: Operating cost 14,381,122,227.18 12,255,445,722.21
Interest expense
Commission charge and
commission expense
Cash surrender value
Net amount of expense of
compensation
Net amount of withdrawal
of insurance contract reserve
Bonus expense of
guarantee slip
Reinsurance expense
Operating tax and extras 32,966,662.80 36,252,178.16
Sales expenses 353,398,338.86 344,388,124.93
Administration expenses 303,141,697.44 279,078,781.03
Financial expenses 119,635,650.08 123,265,888.67
Losses of devaluation of
17,761,520.56 16,672,888.27
asset
Add: Changing income of fair
value(Loss is listed with “-”)
Investment income (Loss is
30,515,319.09 25,020,090.00
listed with “-”)
Including: Investment income
30,515,319.09 25,020,090.00
on affiliated company and joint venture
Exchange income (Loss is
17
listed with “-”)
III. Operating profit (Loss is listed
498,844,348.34 466,439,677.08
with “-”)
Add: Non-operating income 29,276,636.55 27,072,897.87
Less: Non-operating expense 22,274,449.46 30,500,555.57
Including: Disposal loss of
156,912.97 9,027,535.66
non-current asset
IV. Total Profit (Loss is listed with
505,846,535.43 463,012,019.38
“-”)
Less: Income tax expense 98,584,630.53 98,516,506.38
V. Net profit (Net loss is listed with “-”) 407,261,904.90 364,495,513.00
Including: net profit realized
-240,695.14
before consolidation by mergered party
Net profit attributable to owner’s
396,685,115.71 357,075,630.31
of parent company
Minority shareholders’ gains and
10,576,789.19 7,419,882.69
losses
VI. Earnings per share -- --
i. Basic earnings per share 1.377 1.239
ii. Diluted earnings per share 1.377 1.239
VII. Other consolidated income
VIII. Total comprehensive income 407,261,904.90 364,495,513.00
Total consolidated income
attributable to owners of parent 396,685,115.71 357,075,630.31
company
Total consolidated income
10,576,789.19 7,419,882.69
attributable to minority shareholders
Legal representative: Yan Zhigang
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Chi Guoguang
6. Profit Statement of parent company (from year-begin to end of this period)
Prepared by China National Accord Medicines Corporation Ltd.
In RMB
Items Amount in this period Amount in last period
I. Operating revenue 1,871,200,691.97 1,611,320,742.34
Less: operating cost 1,789,158,702.46 1,533,819,509.57
Operating tax and extras 3,500,049.67 4,015,503.39
Sales expenses 35,538,629.68 34,323,702.94
18
Administration expenses 35,407,135.00 40,489,753.67
Financial expenses 6,025,727.14 15,666,378.68
Losses of devaluation of asset 251,017.39 -385,458.17
Add: Changing income of fair
value(Loss is listed with “-”)
Investment income (Loss is
420,352,640.45 342,092,885.99
listed with “-”)
Including: Investment income
30,515,319.09 25,020,090.00
on affiliated company and joint venture
II. Operating profit (Loss is listed
421,672,071.08 325,484,238.25
with “-”)
Add: Non-operating revenue 7,943,421.62 822,021.74
Less: Non-operating expense 2,050.00 270,566.98
Including: Disposal loss of
69,125.07
non-current asset
III. Total Profit (Loss is listed with
429,613,442.70 326,035,693.01
“-”)
Less: Income tax expense -53,305.02 2,298,245.25
IV. Net profit (Net loss is listed with
429,666,747.72 323,737,447.76
“-”)
V. Earnings per share -- --
i. Basic earnings per share
ii. Diluted earnings per share
VI. Other consolidated income
VII. Total comprehensive income 429,666,747.72 323,737,447.76
Legal representative: Yan Zhigang
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Chi Guoguang
7. Consolidated Cash Flow Statement (from year-begin to end of this period)
Prepared by China National Accord Medicines Corporation Ltd.
In RMB
Item Amount in this period Amount in last period
I. Cash flows arising from operating
activities:
Cash received from selling
commodities and providing labor 15,759,715,499.06 12,752,376,314.27
services
Net increase of customer deposit
and interbank deposit
Net increase of loan from central
bank
Net increase of capital borrowed
from other financial institution
19
Cash received from original
insurance contract fee
Net cash received from reinsurance
business
Net increase of insured savings
and investment
Net increase of disposal of
transaction financial asset
Cash received from interest,
commission charge and commission
Net increase of capital borrowed
Net increase of returned business
capital
Refund of taxes and surcharges 8,242,898.04 1,645,597.88
Other cash received concerning
53,709,097.32 82,642,098.78
operating activities
Subtotal of cash inflow arising from
15,821,667,494.42 12,836,664,010.93
operating activities
Cash paid for goods and services 14,595,729,806.54 11,861,241,353.99
Net increase of customer loans and
advances
Net increase of deposits in central
bank and interbank
Cash paid for original insurance
contract compensation
Cash paid for interest, commission
charge and commission
Cash paid for bonus of guarantee
slip
Cash paid to/for staff and workers 382,463,113.16 358,441,169.10
Payments of taxes and surcharges 349,077,917.15 371,596,474.36
Other cash paid concerning
249,583,919.13 233,299,748.68
operating activities
Subtotal of cash outflow arising from
15,576,854,755.98 12,824,578,746.13
operating activities
Net cash flows arising from operating
244,812,738.44 12,085,264.80
activities
II. Cash flows arising from investing
activities:
Cash received from recovering
investment
Cash received from investment
28,152,000.00 13,520,461.47
income
Net cash received from disposal of
fixed, intangible and other long-term 3,028,761.00 54,082,155.99
assets
Net cash received from disposal of
subsidiaries and other units
Other cash received concerning
investing activities
Subtotal of cash inflow from investing
31,180,761.00 67,602,617.46
activities
Cash paid for purchasing fixed,
73,342,076.03 146,451,305.64
intangible and other long-term assets
20
Cash paid for investment
Net increase of mortgaged loans
Net cash received from subsidiaries
151,731.71 55,451,762.22
and other units
Other cash paid concerning
investing activities
Subtotal of cash outflow from investing
73,493,807.74 201,903,067.86
activities
Net cash flows arising from investing
-42,313,046.74 -134,300,450.40
activities
III. Cash flows arising from financing
activities
Cash received from absorbing
investment
Including: Cash received from
absorbing minority shareholders’
investment by subsidiaries
Cash received from loans 598,850,496.45 840,603,970.24
Cash received from issuing bonds 398,400,000.00
Other cash received concerning
400,000,000.00 252,631,051.81
financing activities
Subtotal of cash inflow from financing
998,850,496.45 1,491,635,022.05
activities
Cash paid for debts settlement 674,228,825.54 918,491,964.16
Cash paid for dividend and profit
176,840,535.37 153,290,704.45
distributing or interest paying
Including: Dividend and profit of
minority shareholder paid by 4,966,654.86 915,144.07
subsidiaries
Other cash paid concerning
414,085,233.92 570,193,419.23
financing activities
Subtotal of cash outflow from financing
1,265,154,594.83 1,641,976,087.84
activities
Net cash flows arising from financing
-266,304,098.38 -150,341,065.79
activities
IV. Effect of foreign exchange rate
-6,572.26 8,041.67
changes on cash and cash equivalents
V. Net increase of cash and cash
-63,810,978.94 -272,548,209.72
equivalents
Add: Balance of cash and cash
920,748,043.53 907,884,162.14
equivalents at the period -begin
VI. Balance of cash and cash
856,937,064.59 635,335,952.42
equivalents at the period -end
Legal representative: Yan Zhigang
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Chi Guoguang
21
8. Cash Flow Statement of parent company (from year-begin to end of this period)
Prepared by China National Accord Medicines Corporation Ltd.
In RMB
Item Amount in this period Amount in last period
I. Cash flows arising from operating
activities:
Cash received from selling
commodities and providing labor 1,915,280,492.82 1,662,451,442.57
services
Write-back of tax received
Other cash received concerning
16,077,640.47 16,338,339.91
operating activities
Subtotal of cash inflow arising from
1,931,358,133.29 1,678,789,782.48
operating activities
Cash paid for purchasing
commodities and receiving labor 1,893,911,070.75 1,633,946,690.73
service
Cash paid to/for staff and workers 38,651,909.44 33,994,046.58
Taxes paid 12,077,871.06 20,053,311.69
Other cash paid concerning
26,730,502.96 22,068,405.14
operating activities
Subtotal of cash outflow arising from
1,971,371,354.21 1,710,062,454.14
operating activities
Net cash flows arising from operating
-40,013,220.92 -31,272,671.66
activities
II. Cash flows arising from investing
activities:
Cash received from recovering
investment
Cash received from investment
138,763,600.61 123,264,318.99
income
Net cash received from disposal of
fixed, intangible and other long-term 65,000.00 207,900.00
assets
Net cash received from disposal of
5,424,600.00
subsidiaries and other units
Other cash received concerning
1,490,052,164.08 295,783,271.97
investing activities
Subtotal of cash inflow from investing
1,628,880,764.69 424,680,090.96
activities
22
Cash paid for purchasing fixed,
13,653,720.05 1,799,057.00
intangible and other long-term assets
Cash paid for investment 100,000,000.00 10,000,000.00
Net cash received from
151,731.71 85,598,000.00
subsidiaries and other units
Other cash paid concerning
1,459,100,000.00 594,080,000.00
investing activities
Subtotal of cash outflow from investing
1,572,905,451.76 691,477,057.00
activities
Net cash flows arising from investing
55,975,312.93 -266,796,966.04
activities
III. Cash flows arising from financing
activities
Cash received from absorbing
investment
Cash received from loans 440,000,000.00 160,000,000.00
Cash received from issuing bonds 398,400,000.00
Other cash received concerning
1,265,475,600.48 648,349,929.11
financing activities
Subtotal of cash inflow from financing
1,705,475,600.48 1,206,749,929.11
activities
Cash paid for settling debts 322,000,000.00 130,164,459.99
Cash paid for dividend and profit
103,003,578.81 81,187,208.13
distributing or interest paying
Other cash paid concerning
1,270,743,410.18 800,026,956.78
financing activities
Subtotal of cash outflow from financing
1,695,746,988.99 1,011,378,624.90
activities
Net cash flows arising from financing
9,728,611.49 195,371,304.21
activities
IV. Influence on cash and cash
equivalents due to fluctuation in
exchange rate
V. Net increase of cash and cash
25,690,703.50 -102,698,333.49
equivalents
Add: Balance of cash and cash
160,633,355.13 164,840,499.86
equivalents at the period -begin
VI. Balance of cash and cash
186,324,058.63 62,142,166.37
equivalents at the period -end
Legal representative: Yan Zhigang
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Chi Guoguang
23
II. Audit report
Whether the third quarter report was audited or not
□Yes √No
The third quarter report of the Company has not been audited
24
